Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 8/20 | 0.82 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116352 | 0.72 | MARS1 (1.00) | MARS1MEN1KMT2A | |
| SCHEMBL2731431 | 0.67 | NOTUM (0.53) | MARS1MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL31078777 | 0.67 | NOTUM (0.53) | MARS1MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL117374 | 0.66 | MARS1 (1.00) | MARS1 | |
| SCHEMBL117650 | 0.65 | MARS1 (1.00) | MARS1 | |
| SCHEMBL16615357 | 0.65 | NOTUM (0.53) | MEN1KMT2AALDH1A1NPSR1F2 | |
| SCHEMBL17479508 | 0.65 | MARS1 (0.48) | MARS1ALDH1A1NPSR1GRM5F2 | |
| SCHEMBL17156386 | 0.64 | CACNA1B (0.53) | MARS1CACNA1BALDH1A1PDCD1CD274 | |
| SCHEMBL18134658 | 0.63 | NPC1 (0.63) | MARS1CACNA1BMEN1KMT2AALDH1A1 | |
| SCHEMBL12497363 | 0.63 | NOTUM (0.48) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885CACNA1B 4829/4885SPR 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.